Hello, and welcome back to the Bell Potter Healthcare Conference. My name is Thomas Wakim, and I am really pleased to introduce our next presentation today from Saluda Medical. With us on the line, we have Mike Mathias, the CEO, and Jim Erickson, CFO. Mike and Jim, thank you both for joining us today.
Thanks for having us, Thomas.
Thanks for having us.
As a quick introduction before I pass it over to you for your presentation, Saluda is a medical device company founded on technology spun out of Cochlear. The company has a uniquely differentiated product called the Evoke System, which treats chronic pain. The uniqueness of the Evoke System lies in its ability to detect and tailor nerve stimulation hundreds of times per second, which ultimately leads to deeper and more durable pain relief for patients. Saluda's product is available globally and is expected to generate sales north of $113 million this financial year. With that, Jim and Mike, thanks again for joining us. Please take us through your slide presentation, and we will follow up with some Q&A afterwards.
Thank you, Thomas. This slide just discusses Saluda's value proposition. We believe we have a very differentiated technology addressing two very important challenges that have constrained the spinal cord stimulation market historically. The first is durability, and the second is just the commercial and clinical burden associated with managing spinal cord stimulation patients. Evoke is fundamentally different because it doesn't just deliver stimulation. It measures the neural response created by the stimulation and adjusts therapy based on that response. Our clinical data has demonstrated durable outcomes to 36 months, while our commercial experience increasingly demonstrates a substantially lower programming burden. That second point is important because it connects the clinical differentiation to the economics of the business. If we can provide patients with effective and durable therapy that requires less ongoing intervention, that's better for patients and physicians. It also changes the economics of Saluda.
Our field team can spend more time supporting physicians, new physicians, and new patients, and less time on non-revenue-generating service activities. Next slide, Jim. Spinal cord stimulation is a well-established market, established reimbursement codes, coverage, and payment. It's a large market, a $23 billion addressable market. It's very under-penetrated. Spinal cord stimulation patients remain underserved, and with improved options, we may be able to unlock this large addressable market. Next slide, Jim. The Evoke System, how does it work? The fundamental limitation of spinal cord stimulation is delivering the same stimulation setting that does not create the same neural response in every patient. Every patient's different. Every patient responds to stimulation differently, and in turn, you need a device that not just sends a signal to the spinal cord, but also reads the spinal cord's response to that stimulation. Evoke's leads perform two functions.
It stimulates the spinal cord and measures the resulting neural activation, known as an ECAP. That measurement allows us to identify personalized neural doses and maintain it automatically. The system measures and adjusts on every pulse, responding to changes in position, movement, and physiology. Rather than relying on just the subjective patient feedback, Evoke provides objective physiologic control of the therapy. Evoke stimulates, measures, and adjusts on every pulse. That is the foundation of Saluda's differentiation. Next slide. As we discussed earlier, in addition to durability, the patient's burden, it's traditionally to maintain therapy, requires extensive involvement and reprogramming. As you can see on this graph, every spinal cord stimulation device that is not Evoke or not sensing, the average patient has their device reprogrammed roughly six times per year.
If you look at the Evoke service burden, after about 18 months, our patients only need to be reprogrammed less than one time per year. 61% of those patients after 18 months are not reprogrammed at all. This is the economics of our therapy. Traditional spinal cord stimulation companies have to have large sales forces to manage the service burden necessary to keep patients in therapy. As a result of our sensing technology and our ability to provide a prescribed dose, those patients do not have to be seen as often, and our data suggests less than one time per year afterwards. As a result, our commercial footprint in the field to service patients can be significantly less. Next slide. EVA. EVA is our automatic programming system.
Evoke's data is objective, and we can automate that programming workflow, analyzing the spinal cord, identifying it, looking for the strongest signal, and determining the personalized therapeutic setting. As a result, in the real world, patients respond 92% of the time to their EVA. 67% of them had high responders, 96% of the patients reported satisfaction, 97% reporting a sense of control. This, for the commercial organization, reduces dependency on our individual sales representative, service representative technical skills. It simplifies training and shortens the pathway of representative productivity. EVA objectifies programming and gets patients better outcomes. Next slide. Jim?
Yeah. Thanks, Mike. We recently completed our first quarter of FY 2027, the September quarter. Just as a summary, we've seen some strong growth, really buoyed by the U.S., 26% global growth with a U.S. growth rate of 34%. The real underlying part of the business that we measure most critically is the number of patients implanted. Our U.S. patient implanted number of 838 grew 55% year-over-year, and the number of physicians that were actively implanting the device in the quarter grew 47%. That growth was really driven by the expansion of the U.S. field team that we invested in our FY 2026. More than 60% growth in the number of trained sales reps in FY 2026 going into FY 2027.
That field team now as we end the first quarter, has about 75% of the sales force fully trained, and of that fully trained sales force, covering about 50% of the viable U.S. territories in the U.S. That growth, driven by an expansion of the field team, but also beginning to be driven by not just the adoption of the traditional Evoke System, but also by the expansion into the neurosurgery market. In June, we received FDA approval of our CAP24 paddle lead. This is a paddle lead that accesses the before unaccessed neurosurgery or orthopedic surgical market. We moved this product into full commercial launch in October and are beginning to expand that use across our U.S. commercial footprint. Our long-term growth is something that's really driven by four distinct buckets.
Our current FY 2027 guidance of $113 million-$122 million represents an over 30% CAGR since FY 2026, or sorry, since FY 2024, which was the first full year of our U.S. commercial launch. The four buckets driving our long-term growth, first, expanding into new territories. I mentioned our fully trained U.S. sales force covers approximately 50% of the viable territories in the U.S., leaving a lot of runway still yet to be untapped by expansion of the field team and expansion of further trained sales force. There's also just under 6,000 physicians in the U.S. that perform interventional percutaneous lead implants in SCS, with another 2,000 neurosurgeons that also perform paddle lead-based SCS. Based on our active physician numbers in the most recent quarter, we're only penetrated in about 5% of this existing SCS physician market.
With such early days in penetration, there continues to be a lot of room for growth, for expansion, not just within accounts, but also from expanding into the broader already SCS-using physician base. I mentioned the launch of our new paddle lead. This is really the third bucket of growth drivers. Our new products, the EVA Sensing Technology system, automation of our programming that Mike mentioned before, has been launched globally now and launched in the U.S. for just over a year. The paddle lead gives us access to about $670 million worth of before unaccessed market. This takes the existing percutaneous market in which has been driving our growth to date and increases it by nearly 70%, all being able to be accessed and sold through the existing sales channel.
The number of reps or the expanding reps that I mentioned earlier in the U.S. will be the same sales force selling on both the existing perc market and the new paddle lead market. The last piece of our growth is the new channels. The left side of this chart gives you a sense of the existing SCS market. The $1 billion de novo percutaneous market is just that, the existing market of newly implanted patients, percutaneously placed leads. This is the market that Saluda has been playing in since its commercial launch. Most recently, we have begun to expand beyond that into the high-volume ASC part of the market. We began this part of our market expansion in the second half of FY 2026.
This requires often a volume rebate structure such that we can access a lower price point by committing higher amounts of volume and share from the account to our device. We are in the early stages of expanding into this high-volume ASC part of the market, which gives us access to the full $1 billion of the perc market that we have been selling in to date. The paddle market, with our CAP24 paddle lead launch, expands that market by another $670 million. This 70% increase, as I mentioned, can be sold through our existing sales channel. The last piece of the market is the replacement market. This represents another $500 million of the market that we have not yet accessed. We have begun to talk about strategies we are taking for the longer term to access this more on a competitive replacement basis.
There is a large installed base of patients who have been implanted with SCS of a competitive device, and as Mike mentioned earlier, the largest problem in the SCS market is the lack of durability of that therapy. While they may have been responders initially, as these patients move through their treatment journey, often the efficacy of that treatment begins to wane over time. It is those patients that we believe we can access with the ability to replace an existing SCS system with a Saluda system. We are in the early days of beginning to design some clinical support to give people substantiation of this approach, but with an ability to unlock this competitive replacement part of the market over the longer term. To close, Mike mentioned at the beginning, really two fundamental key problems with the existing SCS market.
The durability of outcomes, this we believe we've addressed, and we've addressed and proven with our EVOKE study, a three-year clinical study where we followed patients out with high responder rates of over 60%, and 83% of patients with greater than 50% pain relief at the three-month mark. Most importantly, a zero explants due to loss of efficacy at three years in this study. The second problem is the cost of managing therapy. Mike mentioned this, that with our low reprogramming rates from the value of the closed-loop technology, and further enhanced with the launch of EVA, there's less than one reprogramming visit per patient per year with the Evoke System. While our most recent quarter was a growth of 26%, we're still very early days in the physician penetration and with the overall market penetration as we continue to expand broader channels within the SCS market.
We believe Saluda has a long runway ahead of its growth as we begin to access these further channels and move to show not just the growth of our sales force and the growth of the business, move to the productivity of that sales force, and prove our ability to move this technology into a profitable state. With that, we'll turn it over to Q&A.
Great. Thank you, Jim, and thanks, Mike, for the run-through. I'd like to start on reprogramming. You touched on it a couple of times there, but maybe just really worth emphasizing here, the advantage of the Evoke System in terms of reprogramming, and specifically the data you're seeing either in the trials or in the real world showing the advantage of lower reprogramming versus what is typically expected with open-loop systems.
Jim, mind if I take it?
Go for it.
Thomas, I appreciate you asking a question that's fundamentally one of the reasons we exist as a company. All other spinal cord stimulation devices deliver electricity to the cord, and there's only one device, the Evoke System, that deals with under-stimulation and over-stimulation effectively to deliver therapy as the patient requires. The delivery and sensing of the technology allows us to create algorithms to keep patients at their appropriate dose. As a result, the patients don't have to come back and get their device managed by another representative. It showed up in the EVOKE study, and now in the real world when you see at scale, we are able to see our patients consistently, after we get through the first 12 months, they're reporting in and seeing their service representative, sales representative for reprogramming less than one time per year.
The published data in the marketplace for traditional non-sensing technologies, which are the ones that exist out in the marketplace today, the reported data suggests that it's somewhere between five and seven times a year a patient has to come back and see a representative. So, that's a reminder that they're in pain. It's a reminder that their device is not working appropriately. We do not have that reminder. We get them through their initial phase of establishing the efficacy, and then the patients are seen less than one time per year. As a result, you look at how many people we have to hire to take care of those patients. First of all, the patients are happier, and second of all, we don't have to have the manpower that our competitors do to support those patients.
Great. Thanks, Mike. I imagine when it comes to actually building out your sales team, not having the reps have to be called countless times by a patient to reprogram their device, how advantageous are you finding that element in terms of building out and hiring some of the sales team? People wanting to join you because they don't have to deal with calls at all hours of the day and night, having to deal with existing service patients.
Yeah. Thomas, that is a real benefit, and it is a reported benefit. I think there were skeptics at the beginning, but when they join the organization, they see what their life is like to manage their territories. They can focus on what they like to do, which is educate the community on the benefits of spinal cord stimulation, and help those patients get great outcomes. As a result, we are able to attract top talent, and those talents can put their skills to use as educating on the benefits of the therapy versus having to reprogram. The lifestyle, but more importantly, just what they do on a quality work basis, it is about educating the community and getting patients into the funnel to be able to take care of them.
Great. All right, just shifting to the paddle lead that you have launched quite recently. This is clearly an area of growth opportunity for the company. Let us talk a bit about the potential for leveraging your existing sales team and the sales channels of customers that they have with the existing perc lead. How easy is it for them to leverage those channels into the new kind of paddle lead and more surgical-based market? Is it a big uplift?
Yeah, we basically are using the same sales force we have today. Each territory has a little bit different mix in terms of percentage of how much paddle and how much percutaneous, but there are territories that are focused more on paddle than perc, but they go inner, based on the needs of the patient. The need of a paddle is an anatomical situation. In any given situation prior to having access to the paddle, we could do a percutaneous trial, and then the patient, we could not get a permanent device in, and we would get sent to a neurosurgeon to put a paddle in, and we would lose that case.
Today, now with the paddle, depending on whatever that patient needs, we can trial that patient appropriately, and then the same sales force, same clinical specialist team is supporting both the neurosurgeon and interventional pain physician to take care of the patient. There really is not a There is a little bit different training required, but the actual taking care of the patient is the same person doing it.
Great. Okay. Jim, I might bring you in here. Let's talk about gross margins for a second. At the moment, gross margins are around about 50% or so, but you've flagged that there are some clear opportunities to improve that in the not-too-distant future. Can you just run us through where you're at in terms of those initiatives to improve the gross margin?
Yeah, that's right, Thomas. You're right. We guided our FY 2027 gross margin to a range of 50%-52%. The market in SCS is clearly in the mid to upper 60%. We know we can get this business there. Quite frankly, the product that we're selling today wasn't quite designed for manufacturability, so this is really a bill of material design fix at its core. We have two new products, a new IPG, which is the impulse generator that is implanted just under the skin that runs the electricity and has the chip with the algorithm in it. We've redesigned it. It will reduce the unit cost. It'll also be smaller, which will be a nice commercial benefit to customers as well. That product is in the later stages of development. It's in design verification, validation.
Our expectations, we haven't really guided to a launch period per se, but we have been saying that our submission to the FDA for that device would be somewhere later this calendar year or very early next calendar year. The new percutaneous lead is another redesign. We've changed the manufacturing process to reduce the unit cost, both from scrap and from labor on that new percutaneous lead. So different than the paddle lead we talked about, we're actually redesigning the existing lead. That is also in late-stage development with a similar type timeline to submission. Once those two get through submission and ultimately approval, and those two devices are the primary devices that we're selling in the marketplace, that should comfortably get the business up into the 60% range.
We've got some further, I'll say, some further adjustments in other ancillary parts of the product portfolio, some further adjustments to the unit cost in both of those areas as well. But those two that can get us into the higher 60%, but it's really those two product launches that become the real levers to get us into that mid-60% range.
Great. Thanks, Jim. While I've got you, let's just touch on cash burn for a moment here. As you're going through this growth period, can you just take a few moments to talk to the outlook for the cash burn profile as you move throughout the course of FY 2027? I know there were some comments in the quarterly about how it's planning to improve.
Yeah. No, good question. This has, of course, been an area of focus for us, obviously for investors as well. We have invested pretty heavily in new sales force. We talked about in our commentary, we've really expanded our U.S. footprint to give us that roughly 50% coverage. That's been an area of focus for us. Those reps are starting to ramp, but they will and are continuing to require additional cash, even as we are at this higher growth rate. Based on the cash that we had on the balance sheet, and our guidance that we had reaffirmed, what we had said is we expect that the cash that we have available should give us runway into about June of next calendar year.
We did have a little bit elevated cash burn in the first fiscal quarter, and we expected that to come down a bit for the remaining quarters, and gave that runway to give people visibility to how much runway we believe we've got. We're focused on making sure we can finance the business through to the next phase of the company's growth and development.
Great. All right, Mike, I want to bring you back in. You touched on the EVA program during your slide presentation. Clearly, it's been a bit of a boon for your sales productivity. Can you just maybe take a moment quickly to re-highlight the advantages of the EVA System? Secondly, how unique is that system to Saluda and the Evoke product? Is this something that others are deploying in the field, or is it inherent to you and your sales force?
Yeah. Thomas, great question. First, it's fundamentally the reason we're able to create EVA, our automatic programming system, is the objective nature of our therapy. We send a signal, we sense a signal, we get an ECAP back. That ECAP, we have trillions of ECAPs recorded, and as a result of machine learning, we're able to figure out how to reproduce this workflow in an automatic way. It does two things. First of all, one, I can train a new sales representative more quickly, significantly quickly, and get them up to speed. Secondly, I can get a patient in a closed-loop therapy much quicker and more consistently as a result of it. We are the only technology in the world that has access to EVA, and it's fundamentally because we measure the response of the cord.
We know what, see the ECAP, we can identify that with our algorithms, and in turn, we can program the patient appropriately. So it's a huge advantage for patients because they get a better experience. Secondly, for our sales force, I can get them up to speed quickly, and they can take care of patients in the field much, much quicker, and ultimately, it's good for both parties.
Great. Yeah, it makes sense that without that objective data, you can't automate the reprogramming.
Correct.
Okay. Well, Mike and Jim, that does just about wrap up the time we have for our presentation today. I want to thank you both for presenting for our conference. Congratulations on the commercial success that you've had over the last few years, and we look forward to that continuing over the near and long term. Thank you very much again.
Thanks, Thomas. Be well. Bye.
Thanks, Thomas, and thanks to Bell Potter. Thanks all.
Great. All right, stay there just one moment. We're going to go to a quick break, and then we'll be back with our next presentation. Thank you.